Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019

Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019

Saved in:
Bibliographic Details
Published in:The Journal of clinical and aesthetic dermatology Vol. 17; no. 7; pp. 17 - 18
Main Authors: Laborada, Jennifer, Shin, Leah, Lee, Claudia, Shahsavari, Shahin, Egeberg, Alexander, Wu, Jashin J
Format: Journal Article
Language:English
Published: United States Matrix Medical Communications 01-07-2024
Subjects:
Letters to the Editor
immunomodulators
cost
healthcare spending
Biologics
psoriasis
medicare
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
FUNDING.: No funding was provided for this article.
DISCLOSURES.: Dr. Laborada, Dr. Shin, Dr. Lee, Mr. Shahsavari, and Dr. Egeberg report no conflicts of interest. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health (Ortho Dermatologics), Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health.
ISSN:1941-2789
2689-9175